Form 8-K - Current report:
SEC Accession No. 0001104659-25-108839
Filing Date
2025-11-10
Accepted
2025-11-10 08:00:09
Documents
14
Period of Report
2025-11-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K avbp-20251110x8k.htm   iXBRL 8-K 39892
2 EX-99.1 avbp-20251110xex99d1.htm EX-99.1 186793
3 GRAPHIC avbp-20251110xex99d1001.jpg GRAPHIC 3635
  Complete submission text file 0001104659-25-108839.txt   361364

Data Files

Seq Description Document Type Size
4 EX-101.SCH avbp-20251110.xsd EX-101.SCH 2669
5 EX-101.LAB avbp-20251110_lab.xml EX-101.LAB 16577
6 EX-101.PRE avbp-20251110_pre.xml EX-101.PRE 10710
16 EXTRACTED XBRL INSTANCE DOCUMENT avbp-20251110x8k_htm.xml XML 5101
Mailing Address 18 CAMPUS BLVD. SUITE 100 NEWTOWN SQUARE PA 19073-3269
Business Address 18 CAMPUS BLVD. SUITE 100 NEWTOWN SQUARE PA 19073-3269 240-780-6356
ArriVent BioPharma, Inc. (Filer) CIK: 0001868279 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41929 | Film No.: 251464408
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)